CAS NO: | 65710-07-8 |
规格: | ≥98% |
包装 | 价格(元) |
50mg | 电议 |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
1g | 电议 |
Molecular Weight (MW) | 637.66 |
---|---|
Formula | C21H41N5O11.xH2O4S |
CAS No. | 65710-07-8 |
Storage | -20℃ for 3 years in powder form |
-80℃ for 2 years in solvent | |
Solubility (In vitro) | DMSO: <1 mg/mL |
Water: 100 mg/mL (156.82 mM) | |
Ethanol: <1 mg/mL | |
Other info | Chemical Name: (2R,3R,4S,5S,6S)-2-[[(2R,3S,4R,4aR,6S,7R,8aS)-7-amino-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxycyclohexyl]oxy-4-hydroxy-3-(methylamino)-2,3,4,4a,6,7,8,8a-octahydropyrano[3,2-b]pyran-2-yl]oxy]-5-amino-6-(hydroxymethyl)oxane-3,4-diol sulfuric acid InChi Key: WGLYHYWDYPSNPF-RQFIXDHTSA-N InChi Code: InChI=1S/C21H41N5O11.H2O4S/c1-26-11-14(30)18-8(33-20(11)37-21-16(32)13(29)10(25)9(4-27)34-21)3-7(24)19(36-18)35-17-6(23)2-5(22)12(28)15(17)31;1-5(2,3)4/h5-21,26-32H,2-4,22-25H2,1H3;(H2,1,2,3,4)/t5-,6+,7-,8+,9-,10-,11+,12+,13+,14-,15-,16-,17-,18+,19+,20-,21-;/m1./s1 SMILES Code: O[C@H]1[C@@H](O[C@@H]2[C@@H](NC)[C@@H](O)[C@]3([H])[C@@](C[C@@H](N)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](N)C[C@@H]4N)O3)([H])O2)O[C@H](CO)[C@@H](N)[C@@H]1O.O=S(O)(O)=O |
Synonyms | Ai3-29795; Ai3 29795; Ai 3-29795; Apramycin sulphate; Nebramycin II |
In Vitro | In vitro activity: Apramycin consumption at farm level is most probably driving the increasing occurrence of apramycin/gentamicin cross-resistant [aac(3)-IV positive] E. coli in diseased pigs and healthy finishers at slaughter. Apramycin inhibits A. pleuropneumoniae FMV 87-682 with MIC50 of 8 mg/L. Apramycin (1/4 MIC) in the medium decreases the rate of growth of the bacterial strains tested, and causes the postantibiotic effect (PAE) up to 5 hours. Apramycin significantly reduces the haemolytic activity of A. pleuropneumoniae and affects the capsular material production of this isolate and of one isolate of P. multocida (type A). Apramycin induces translation errors, as assayed by incorporation of leucine, isoleucine and serine, although this effect occurs only to a limited extent, in cell-free systems from Escherichia coli programmed with poly(U). Apramycin inhibits the translocation step of protein synthesis both in vivo, in protoplasts of Bacillus megaterium, and in vitro, in cell-free systems from E. coli. |
---|---|
In Vivo | Apramycin (225 mg/L) totally suppresses mortality and significantly reduces Salmonella excretion in comparison with non-treated chicks. |
Animal model | Chicks |
Formulation & Dosage | 225 mg/L |
References | J Antimicrob Chemother. 2006 Jul;58(1):101-7; Int J Antimicrob Agents. 1999 Aug;12(3):229-37; Immunopharmacol Immunotoxicol. 1992;14(1-2):191-205. |